中图分类号R979.5 文献标志码A 文章编号 1001-0408(2025)13-1677-06

    DOI 10.6039/j.issn.1001-0408.2025.13.21

    Research progress in antibody drug therapy for relapsed/refractory diffse large B-cellymphoma

    SUN Yanyan，ZHAO Weichen，HE Chunyuan，XIA Yimiao，ZHOU Wei，ZHEN Yuanyuan，JIANG Junjie，WANG Facai[Dept.of Pharmacy，Lu'an Hospital of Anhui Medical University(Lu'an People’s Hospital)，Anhui Lu'an 237005，China]

    ABSTRACTDiffselargeB-celymphoma(DLBCL)isahighlyheterogeneousdisease.Although standardfirstlineregimens can cure 550% ofpatients，approximately one-third of them develop relapsed/refractory DLBCL( .r/r DLBCL).Consequently， immunotherapy targeting molecular abnormalities has become pivotal for managing r/r DLBCL. The results of this review show that withadvances inunderstanding DLBCLpathogenesisandthetumor immunemicroenvironment，antibody-basedtherapies haveevolvedrapidly，progressing from monoclonalantibodies(e.g.，rituximab，tafasitamab)to bispecificantibodies(e.g.， odronextamab，gloftamab，epcoritamab)andantibody-drugconjugate(e.g.，polatuzumabvedotin，loncastuximabtesirine).These engineered agents enhance immune cytotoxicity and tumor-specific targeting ......